35636-10-3

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
1-Benzyl-4-chloro-5-azaindole serves as a key building block for the synthesis of various pharmaceuticals and agrochemicals. Its unique structure and functional groups contribute to the development of new molecules with therapeutic and pesticidal properties.
Used in Antiviral Applications:
1-Benzyl-4-chloro-5-azaindole is studied for its antiviral properties, potentially inhibiting the replication and infectivity of viruses, making it a candidate for the development of antiviral drugs.
Used in Antitumor Applications:
1-Benzyl-4-chloro-5-azaindole has been investigated for its antitumor properties, showing promise in inhibiting the growth and proliferation of cancer cells, thus contributing to the development of novel anticancer agents.
Used in Analytical and Biological Research:
1-Benzyl-4-chloro-5-azaindole's potential as a fluorescent probe makes it valuable in analytical and biological research. Its fluorescence properties can be utilized for detecting and monitoring various biological processes and interactions, enhancing the understanding of complex biological systems.

Upstream product

• 100-39-0 benzyl bromide 
• 60290-21-3 4-chloro-1H-pyrrolo-[3,2-c]-pyridine 
• 26956-47-8 1-benzyl-4,5-dihydro-4-oxopyrrolo<3,2-c>pyridine 

Downstream Products

• 106689-62-7 benzyl-1 (α-hydroxyethyl)-2 chloro-4-1H-pyrrolo<3,2-c>pyridine 
• 35801-12-8 benzyl-(1-benzyl-1H-pyrrolo[3,2-c]pyridin-4-yl)-amine 
• 102998-41-4 benzyl-1 (α-methoxy-4' phenyl α-hydroxy)ethyl-2 chloro-4 pyrrolo<3,2-c>pyridine 
• 102998-48-1 1-benzyl-4-chloro-2-(1-(4-methoxyphenyl)vinyl)-1H-pyrrolo[3,2-c]pyridine 
• 102998-49-2 1-Benzyl-2-[1-(4-methoxy-phenyl)-vinyl]-1,5-dihydro-pyrrolo[3,2-c]pyridin-4-one 
• 102998-52-7 1-Benzyl-2-[1-(4-methoxy-phenyl)-ethyl]-1,5-dihydro-pyrrolo[3,2-c]pyridin-4-one 
• 102998-55-0 benzyl-1 (α-methoxy-4' phenyl)ethyl-2 chloro-4 pyrrolo<3,2-c>pyridine 
• 102998-58-3 benzyl-1 (α-p-methoxyphenyl)ethyl-2 formyl-3 chloro-4 pyrrolo<3,2-c>pyridine 
• 106689-63-8 benzyl-1 acetyl-2 chloro-4-1H-pyrrolo<3,2-c>pyridine 
• 106689-70-7 acide β-(benzyl-1 chloro-4-1H-pyrrolo<3,2-c>pyridyl-2)crotonique 
• 106689-68-3 (E)-3-(1-Benzyl-4-chloro-1H-pyrrolo[3,2-c]pyridin-2-yl)-but-2-enoic acid ethyl ester 
• 637000-19-2 tert-butyl 4-(1-benzyl-1H-pyrrolo[3,2-c]pyridin-4-yl)piperazine-1-carboxylate 

Relevant academic research and scientific papers

Structure-Based Design and Optimization of FPPQ, a Dual-Acting 5-HT3and 5-HT6Receptor Antagonist with Antipsychotic and Procognitive Properties

In line with recent clinical trials demonstrating that ondansetron, a 5-HT3receptor (5-HT3R) antagonist, ameliorates cognitive deficits of schizophrenia and the known procognitive effects of 5-HT6receptor (5-HT6R) antagonists, we applied the hybridization strategy to design dual-acting 5-HT3/5-HT6R antagonists. We identified the first-in-class compoundFPPQ, which behaves as a 5-HT3R antagonist and a neutral antagonist 5-HT6R of the Gs pathway.FPPQshows selectivity over 87 targets and decent brain penetration. Likewise,FPPQinhibits phencyclidine (PCP)-induced hyperactivity and displays procognitive properties in the novel object recognition task. In contrast toFPPQ, neither 5-HT6R inverse agonist SB399885 nor neutral 5-HT6R antagonist CPPQ reversed (PCP)-induced hyperactivity. Thus, combination of 5-HT3R antagonism and 5-HT6R antagonism, exemplified byFPPQ, contributes to alleviating the positive-like symptoms. Present findings reveal critical structural features useful in a rational polypharmacological approach to target 5-HT3/5-HT6receptors and encourage further studies on dual-acting 5-HT3/5-HT6R antagonists for the treatment of psychiatric disorders.

NEW COMPOUNDS USEFUL FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS

The present invention relates to compounds of the general formula (I), wherein P is sulfone or sulfonamide; and A, B, W, X, Y and R3 are as defined in the description;to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the prophylaxis and treatment of medical conditions relating to obesity, type II diabetes, and/or CNS disorders, to achieve reduction of body weight and of body weight gain.